文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

下一代HIV基因分型检测28种抗逆转录病毒药物耐药突变的设计与评估

Design and Evaluation of Next-Generation HIV Genotyping for Detection of Resistance Mutations to 28 Antiretroviral Drugs Across 5 Major Classes Including Lenacapavir.
PubMed 文献 · Clin Infect Dis · 2025-01-01

研究开发了便携式HIV基因分型平台PHG,结合低成本下一代测序与云计算,筛查5大类28种抗逆转录病毒药物(含来那卡帕韦)耐药。在3个队列中,PHG与标准检测及UMI高保真测序结果一致性高,检出1例2个主要LEN耐药突变,并发现频率低于20%的少数变异和跨类连锁耐药。

要点

  • PHG可检测5大类28种药物耐药,含来那卡帕韦(LEN)。
  • 在3个队列中与标准检测及UMI测序结果多数一致。
  • 10%检测限可检出频率低于20%的少数耐药变异。

核心结论

  • PHG较标准HIV基因分型有显著改进,可低成本、高通量地深入揭示LEN耐药、少数变异和跨类耐药。

研究设计与样本

  • 开发便携式HIV基因分型平台PHG,结合低成本下一代测序与云计算。
  • 分析3个研究队列,将PHG耐药结果与标准检测及UMI标记高保真测序数据比较。

主要发现

  • PHG在1名参与者中检出2个主要LEN耐药突变,并经额外独立测序运行确认。
  • 在3个队列中,PHG在多数受检标本中检出的耐药突变与标准基因分型及UMI标记一致。
  • PHG的10%检测限减少假阳性,并检出频率低于20%的少数变异。
  • PHG检出经UMI确认的跨类连锁耐药突变,包括1名报告使用长效卡博特韦和利匹韦林的参与者。
  • 观察到跨类连锁耐药突变持续多年。

关键数值与推荐

  • PHG筛查5大类28种抗逆转录病毒药物的耐药,包括LEN。
  • PHG检测限为10%。
  • 检出少数变异频率低于20%。

临床怎么用

  • PHG可用于低成本、高通量筛查HIV耐药,包括LEN耐药和少数变异。
  • 检测跨类连锁耐药有助于识别复杂耐药及既往长效药物使用相关耐药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The emergence and spread of human immunodeficiency virus (HIV) drug-resistant strains present a major barrier to effective lifelong antiretroviral therapy. The anticipated rise in long-acting subcutaneous lenacapavir (LEN) use, along with the increased risk of transmitted resistance and pre-exposure prophylaxis-associated resistance, underscore the urgent need for advanced genotyping methods to enhance clinical care and prevention strategies. METHODS: We developed the portable HIV genotyping (PHG) platform, which combines cost-effective next-generation sequencing with cloud computing to screen for resistance to 28 antiretroviral drugs across 5 major classes, including LEN. We analyzed 3 study cohorts and compared our drug-resistance findings with standard-care testing results and high-fidelity sequencing data obtained through unique molecular identifier (UMI) labeling. RESULTS: PHG identified 2 major LEN-resistance mutations in 1 participant, confirmed by an additional independent sequencing run. Across 3 study cohorts, PHG consistently detected the same drug-resistance mutations as standard-care genotyping and high-fidelity UMI labeling in most tested specimens. PHG's 10% limit of detection minimized false-positive results and enabled identification of minority variants with less than 20% frequency, pointing to underdiagnosis of drug resistance in clinical care. Furthermore, PHG identified linked cross-class resistance mutations, confirmed by UMI labeling, including linked cross-resistance in a participant who reported use of long-acting cabotegravir and rilpivirine. We also observed multiyear persistence of linked cross-class resistance mutations. CONCLUSIONS: PHG demonstrates significant improvements over standard-care HIV genotyping, offering deeper insights into LEN resistance, minority variants, and cross-class resistance using a low-cost, high-throughput portable sequencing technology and publicly available cloud computing.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Park SY, Takayama C, Ryu J, et al. Design and Evaluation of Next-Generation HIV Genotyping for Detection of Resistance Mutations to 28 Antiretroviral Drugs Across 5 Major Classes Including Lenacapavir. Clin Infect Dis. 2025. PMID: 40826811. doi:10.1093/cid/ciaf458

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。